No description available.

While the classical function of myelin is to facilitate saltatory conduction, this membrane and the myelin-making oligodendrocytes (OLGs) are now recognized as regulators of plasticity and remodeling in the central nervous system (CNS). Thus, OLG maturation and myelination are highly vulnerable processes along CNS development. We previously showed that rat brain myelination is altered by perinatal exposure to buprenorphine, an opioid analogue in clinical trials for the treatment of pregnant opioid addicts. We now found that the in vivo effects on myelination could result from direct alteration in the balance between μ-opioid receptor (MOR) and nociceptin/orphanin FQ receptor (NOPR) activities in the OLGs. Furthermore, we found that myelination could also be affected by the FDA-approved methadone. A delicate balance between MOR and NOPR signaling may play a crucial role timing OLG maturation and myelin formation and exogenous opioids may disrupt this interplay, altering the developmental pattern of brain myelination.

Hormis leur implication dans les fonctions de reproduction, de développement et du maintien des caractères mâles, les androgènes (principalement la testostérone et la dihydrotestostérone, DHT) sont des hormones stéroïdiennes capables d’influencer plusieurs structures et fonctions du système nerveux. En effet, durant le développement, les androgènes ont un effet masculinisant sur le système nerveux central (SNC) le rendant sexuellement dimorphique. Chez les rongeurs mâles adultes, la substance blanche est plus volumineuse et les oligodendrocytes, cellules myélinisantes du SNC, sont plus nombreux. Cette différence est abolie après castration des mâles ; ce qui suggère l'implication de la testostérone dans le dimorphisme des oligodendrocytes et de la myéline.D’une part, mon travail de thèse visait à démontrer l’implication des androgènes et de leur récepteur (AR) dans l’établissement de ce dimorphisme. Nos résultats confirment l'implication de la testostérone et démontrent que son effet est médié par AR. En effet les corps calleux (CC) des souris mâles adultes ayant un AR non fonctionnel dans l'ensemble de l'organisme (souris Tfm) ou invalidé spécifiquement dans les cellules neurales (souris ARNesCre), présentent 20 à 30% moins d'oligodendrocytes et de surfaces myélinisées que ceux des contrôles. En outre, nos résultats montrent que ce dimorphisme apparait dès le dixième jour postnatal. De manière intéressante, le traitement pharmacologique des souriceaux mâles par un antagoniste du AR (flutamide) et des souriceaux femelles par l’agoniste d'AR (la DHT), pendant les dix premiers jours après la naissance inverse respectivement leurs profils oligodendrocytaires, suggérant un rôle organisationnel d'AR dans la substance blanche.D’autre part, mon sujet consistait à montrer l'importance de la testostérone et du AR dans la réparation de la myéline dans un modèle de démyélinisation de la moelle épinière des souris par injection stéréotaxique de lysolécithine. Nos résultats montrent que le traitement pendant 4 semaines des animaux par la testostérone permet le recrutement des oligodendrocytes et la réparation de la myéline dans les zones lésées. Il est à noter (1) qu’en absence de la testostérone ou d'AR, la réparation de la myéline est inefficace et se fait par des composants de la myéline périphérique et (2)que la présence des astrocytes semble nécessaire pour l’effet remyélinisant de la testostérone. Afin de mieux comprendre le ou les mécanisme(s) d'action(s) de la testostérone et du AR dans les processus de myélinisation et de remyélinisation, nous avons réalisé une étude transcriptomique comparative entre les animaux lésés et traités ou non avec la testostérone pour déterminer les gènes cibles et les voies de signalisations impliquées dans ces processus. Les résultats permettront probablement de définir une nouvelle cible thérapeutique pour les maladies démyélinisantes telle que la sclérose en plaques. / Androgens (mainly testosterone and dihydrotestosterone, DHT) are steroid hormones that are involved in reproduction functions, development and maintenance of male characteristics. They can also influence several structures and functions of the nervous system. Indeed, during development, androgens have a masculinizing effect on the central nervous system (CNS) making it sexually dimorphic. In addition, in adult male rodents,the white matter is larger and presents more oligodendrocytes, myelinating cells of the CNS. This difference is abolished after castration of males ; witch suggests the involvement of testosterone in the dimorphism of oligodendrocytes and myelin.One aim of my thesis was to study the involvement of androgens and their receptor (AR) in the establishment of this dimorphism. Our results confirm that testosterone is involved and demonstrate that its effect is mediated by AR. Indeed, the corpus callosum (CC) of adult male mice having a non-functional AR in the entire body (Tfm mice) or invalidated specifically in neural cells, (ARNesCre mice) have 20 to 30% fewer oligodendrocytes and myelinated area than those of controls. Moreover, our results show that this dimorphism appears early during postnatal life. Interestingly, pharmacological treatment of male pups with an AR antagonist (flutamide) and female ones with an AR agonist (DHT) during the first ten days after the birth reverses their oligodendrocytic profiles. These results suggest an organizational role of the AR in the white matter development.The aim of the second part of my study was to investigate the importance of testosterone and the AR in myelin repair in a rodent model of spinal cord demyelinationby stereotactic injection of lysolecithin. Our results show that a 4 weeks testosterone treatment allows the recruitment of oligodendrocyte and myelin repair. Interestingly, in the absence of testosterone or the AR, myelin repair was ineffeciant and was done by components of peripheral myelin. Moreover, the presence of astrocytes seems necessary for the remyelinating effect of testosterone since myelin repair was confined to astrocyte populated area.An important goal of my work is to better understand the mechanism of action of testosterone and the AR in the process of myelin formation and repair. For this, we performed a comparative transcriptomic study between animals injected or not with LPC than treated or not with testosterone to determine new target genes and signaling pathways involved in these processes. The results will probably define a new therapeutic target for demyelinating diseases such as multiple sclerosis.

No description available.

No description available.

La phénylcétonurie (PCU est une maladie métabolique génétique causée par une déficience d'activité phénylalanine hydroxylase (PAH). Une hypomyélinisation du cerveau a été documentée chez les patients non traités, mais sa pathophysiologie reste floue. Nous avons investigué l'influence de la phénylalanine (Phe), phénylpyruvate (PP) et phénylacétate (PA) sur les oligodendrocytes. Nous avons premièrement montré dans un modèle murin de PCU que le nombre d'oligodendrocytes n'était pas différent dans le corps calleux entre animaux PCU et sains. Ensuite, en utilisant la technique des co-cultures myélinisantes nous avons pu déterminer que Phe, PP et PA n'ont pas d'effet direct sur la synthèse des gaines de myéline. Ces données indiquent que ces trois composés n'exercent probablement pas de rôle direct dans l'hypomyélinisation du système nerveux central constatée dans le cadre de la PCU. Ces données suggèrent donc des mécanismes d'action indirects. De plus, nous avons investigué la faisabilité d'un modèle de thérapie génique pour la PCU. Celui-ci implique la transduction ex vivo d'hépatocytes ou cellules souches mésenchymateuses par un vecteur lentiviral puis leur implantation dans le foie de l'organisme receveur. Phenylketonuria (PKU) is a metabolic genetic disease characterized by deficient phenylalanine hydroxylase (PAH) enzymatic activity. Brain hypomyelination has been reported in untreated patients, but its mechanism remains unclear. We therefore investigated the influence of phenylalanine (Phe), phenylpyruvate (PP), and phenylacetate (PA) on oligodendrocytes. We fisrt showed in a mouse model of PKU that the number of oligodendrocytes is not different in corpus callosum sections from adult mutants or from control brains. Then, using enriched oligodendroglial cultures, we detected no cytotoxic effect of high concentrations of Phe, PP, or PA. Finally, we analyzed the impact of Phe, PP, and PA on the myelination process in myelinating cocultures using both an in vitro index of myelination, based on activation of the myelin basic protein (MBP) promoter, and the direct quantification of myelin sheaths by both optical measurement and a bioinformatics method. None of these parameters was affected by the increased levels of Phe or its derivatives. Taken together, our data demonstrate that high levels of Phe, such as in PKU, are unlikely to directly induce brain hypomyelination, suggesting involvement of alternative mechanisms in this myelination defect. Moreover, we investigated the feasibility of a gene therapy for phenylketonuria. This project involved the ex vivo transduction of hepatocytes and mesenchymal stem cells with lentivirus vector and the engraftment of these cells in the liver's recipient.

Multiple sclerosis and other myelin diseases affect the quality of life many people. In the United States alone, multiple sclerosis afflicts as many as 400,000 individuals. Myelin, which is attacked by multiple sclerosis, plays a critical role in maintaining the healthy function of the adult nervous system. There are many model systems that study myelin and its formation and loss. Our lab investigates the cuprizone model of demyelination and remyelination. The cuprizone model is commonly believed only to affect adult oligodendrocytes, which it kills. The current study investigates whether other cells in the oligodendrocyte line, such as oligodendrocyte progenitor cells, might also be susceptible to the toxic effects of cuprizone. Oligodendrocyte progenitor cells may play an important role in repairing and replacing myelin after demyelinating insults. So any effect that the model has on these cells may be relevant to the use of the model for studying remyelination. In order to evaluate the potential effects of cuprizone, dividing cells in adult mice were labeled with the proliferation marker, Bromodeoxyuridine (BrdU). Immunohistochemical labeling of BrdU shows that the number of actively dividing cells seen in the subventricular and subgranular zones sharply and dramatically decreases after just 1 week on cuprizone. In the following weeks, the number of dividing cells increases, but even after 3 weeks of recovery without cuprizone, the number of BrdU+ cells does not return to control levels. These results may have significant ramifications in the interpretation of results obtained from the cuprizone model, and this finding must be considered in selecting a model for future demyelination studies.

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by demyelination and loss of oligodendrocytes (OLGs), the CNS myelin-producing cells. Thus, understanding the mechanisms that control OLG development can provide valuable knowledge regarding remyelination therapies for MS. This disease is thought to result from an autoimmune attack towards myelin. FTY720, an immunomodulator under evaluation for MS treatment is a sphingosine-1-phosphate (S1P) analog. We found before that S1P plays a crucial role in the NT-3-mediated survival of OLGs, an observation that led us to investigate whether FTY720 could have any effect on these cells. Our studies demonstrate that FTY720 indeed has a direct effect on OLG progenitors, protecting them from apoptotic death through a mechanism involving ERK1/2 and Akt activation. However, another key finding of our study was that this drug arrested OLG differentiation, an effect counteracted by NT-3 which not only enhanced the survival of OLG progenitors but also stimulated their maturation. Furthermore, NT-3 induced an increase in myelin basic protein (MBP) levels in the absence of effects on MBP gene promoter activation or mRNA expression. These observations suggested that NT-3 up-regulated MBP levels by a posttranscriptional mechanism raising the question of whether this neurotrophin could have a more general positive effect on the expression of other OLG proteins. In agreement with this idea, we found that NT-3 also induced the expression of the myelin proteins MAG and MOG. Additionally, [35S]-Methionine labeling indicated a 50% increase in de novo protein synthesis following only a 15 min exposure to NT-3. Such a rapid increase in protein synthesis reinforced the idea that NT-3 plays a crucial role regulating protein expression by posttranscriptional mechanisms. In support of this possibility, we found that NT-3 stimulated the phosphorylation of the initiation factor eIF4E and its inhibitory partner 4EBP1, both essential players in mediating cap-dependent protein synthesis. This stimulation involved the activation of ERK1/2 and PI3K/mTOR mediated signaling pathways. To our knowledge, this is the first study on the regulation of translation initiation in OLGs and the first report describing the potential role of NT-3 as an activator of initiation.

In the brain, axons are wrapped by myelin sheaths which ensure fast saltatory conduction of impulses and provide metabolic support. In multiple sclerosis (MS), the myelin sheaths are lost which leaves the axon denuded. This not only results in slower conduction of action potentials, but if prolonged, can also lead to axon death due to the loss of metabolic support. This neurodegeneration is the main cause of permanent disability in multiple sclerosis patients. The axon death and disability which stem from it could be prevented by restoring the myelin wrap before axon damage has occurred. This remyelination process is carried out by oligodendrocyte precursor cells which are present throughout life. To remyelinate, OPCs migrate to the area of damage and differentiate into myelinating oligodendrocytes which ensheathe axons with new myelin. In multiple sclerosis, this process occurs but is insufficient to overcome the damage. Therefore, central to the therapeutic efforts in multiple sclerosis is the aim to improve endogenous remyelination. Enhancing recruitment of oligodendrocyte precursor cells (OPCs) to the areas of damage is a clinically unexplored target. To investigate the therapeutic potential of OPC recruitment modulators, I have looked at 2 different targets involved in migration NDST1/HS and Sema3A/NP1. The first target, heparan sulfate (HS) is a proteoglycan which is important to OPC migration, investigated by Pascale Durbec's group in France. In a demyelinating mouse model, its key synthesising enzyme, NDST1, is upregulated by oligodendroglia in a belt around the lesion to aid OPC recruitment. Loss of NDST1 in oligodendrocytes was found to impair remyelination and reduce OPC migration in mice. In collaboration with them, I investigated the relevance of this molecule in post-mortem MS human tissue. I found that in human as well as mouse, NDST1 was primarily expressed by oligodendroglia. The protein level and the proportion of oligodendroglia expressing NDST1 was increased in MS compared to control indicating NDST1 upregulation as a disease response in human. We also found that low numbers of NDST1+ oligodendroglia correlate with bigger sizes of lesions and chronic lesion types that fail to repair, highlighting its importance in repair. Moreover, high numbers of NDST1+ cells in a patient correlated with increased remyelination potential. This indicates that in human, intra-patient variation in NDST1 level may explain differences in potential for endogenous repair. Secondly, I looked at Sema3A, a chemorepulsive molecule which is upregulated in demyelinated injury rodent models aswell as multiple sclerosis lesions, particularly in OPC-depopulated chronic active lesions. Research has consistently found that the level of Sema3A negatively correlates to remyelination because Sema3A hinders OPC migration. This has highlighted Sema3A as a potential target to improve OPC recruitment in MS however the size and shape of the molecule make it hard to design therapeutics against it. Therefore, I looked at its druggable receptor, Neuropilin 1 (NP1), to see whether inhibition of NP1 had the same positive effect on OPC recruitment and remyelination as lowering the level of Sema3A. NP1 is a tyrosine kinase receptor for both Sema3A and vascular endothelial growth factor (VEGF) and is found in many cell types. To check if NP1 inhibition is beneficial, I assessed remyelination in a mouse where the Sema3A binding site of NP1 has been mutated to prevent Sema3A binding and exerting its effect. This is a proxy for a (currently unavailable) ideal NP1 inhibitor of the Sema3A site only. Contrary to my expectations, OPC recruitment and remyelination in the mutant mice were not improved. However, the NP1 mutation resulted in an altered immune response. To exclude the possibility that no improvement in the OPC recruitment and remyelination of those mice was seen because it was negated by the altered immune response, I explored a cell specific mutant mouse in which NP1 was deleted in oligodendroglia only. In this mutant as well, I did not see improvement of OPC recruitment and remyelination. I therefore propose that Neuropilin 1 is not imperative for Sema3As action in remyelination and is not suitable as a therapeutic target in multiple sclerosis. Loss of the whole NP1, but not loss of the Sema3A site also resulted in biggermyelinated and unmyelinated axons as well as a different myelin thickness post remyelination. This showed that VEGF and the VEGF site on NP1 in oligodendroglia have a previously unknown but important role in determining axon size and myelin thickness which should be further investigated. To further elucidate those results in a simple system, I looked at how Sema3A, NP1-Sema3A inhibitors, VEGF and NP1-VEGF inhibitor affect OPC behaviour. I confirmed Sema3As chemorepulsive effect but also showed that at different concentrations it can improve proliferation and survival of OPCs. Inhibiting the Sema3A site and the VEGF site of NP1 by specific blocking antibodies also affects OPC proliferation and maturation. This suggested that NP1s ligands are involved in more than just OPC migration. In summary, this work supports the relevance of the mouse findings that NDST1 is upregulated in demyelination and important for repair for human illustrating that it might be a suitable therapeutic target to investigate. However, despite the importance of Sema3A in MS models, its only reported receptor, NP1, is not essential for Sema3As action. Therefore, it is an unsuitable therapeutic target. The fact that NP1 is an inappropriate drug target for MS is further demonstrated by the involvement of its ligands in multiple OPC behaviours both in positive and negative aspects.

Neonatal hydrocephalus is a common neurological disorder leading to expansion of the cerebral ventricles. This disease is associated with significant morbidity and mortality and is often fatal if left untreated. Hydrocephalus was first described over 2500 years ago by Hippocrates, the father of medicine, and remains poorly understood today. Current therapies still rely on invasive procedures developed over 60 years ago that are associated with high failure and complication rates. Thus, the identification of molecular mechanisms and the development of non-invasive medical treatments for neonatal hydrocephalus are high priorities for the medical and scientific communities. The prevailing doctrine in the field is that hydrocephalus is strictly a "plumbing problem" caused by impaired cerebrospinal fluid (CSF) flow. Recently, animal models with impaired cilia have provided insight into the mechanisms involved in communicating (non-obstructive) hydrocephalus. However, as a result of a poor understanding of hydrocephalus, no animal studies to date have identified an effective non-invasive treatment. The goal of this thesis project is to investigate the molecular mechanisms underlying this disease and to identify a non-invasive, highly effective treatment strategy. In Chapter 2, we utilize a novel animal model with idiopathic hydrocephalus, mimicking the human ciliopathy Bardet-Biedl Syndrome (BBS), to examine the role of cilia in hydrocephalus. We find that these mice develop communicating hydrocephalus prior to the development of ependymal "motile" cilia, suggesting that this phenotype develops as a result of dysfunctional "primary" cilia. Primary cilia are non-motile and play a role in cellular signaling. These results challenge the current dogma that dysfunctional motile cilia underlies neonatal hydrocephalus and implicate a novel role for primary cilia and cellular signaling in this disease. Chapter 3 focuses on identifying the link between primary cilia and neonatal hydrocephalus. In this chapter, we report that disrupting the molecular machinery within primary cilia leads to faulty PDGFRα signaling and the loss of a particular class of neural progenitor cells called oligodendrocyte precursor cells (OPCs). We find that the loss of OPCs leads to neonatal hydrocephalus. Importantly, we identify the molecular mechanism underlying both the loss of OPCs and the pathogenesis of neonatal hydrocephalus. Chapter 4 explores the therapeutic potential of targeting the defective cellular signaling pathways to treat neonatal hydrocephalus. By targeting the faulty signaling, we restore normal development of oligodendrocyte precursor cells, and curtail the development of hydrocephalus. This work challenges the predominant view of hydrocephalus being strictly a "plumbing problem" treatable solely by surgical diversion of CSF. Here, we propose that hydrocephalus is a neurodevelopmental disorder that can be ameliorated by non-invasive means. Importantly, we introduce novel molecular targets and a non-invasive treatment strategy for this devastating disorder. To our knowledge, we are the first to successfully treat neonatal hydrocephalus in any model organism by targeting neural progenitor cells.